ENA Respiratory has announced the successful completion of Part A of its Phase IIa community study of INNA-051, a once-weekly dry powder nasal spray designed to prime the body's natural antiviral defences against a broad range of respiratory viruses.
The spray targets the nasal passage — the primary entry point for pathogens such as influenza, RSV, rhinovirus and coronaviruses — and is intended to help the body mount a faster response upon exposure.
The POSITS study enrolled 200 participants across five US sites, including the Center for Vaccine Development and Global Health at the University of Maryland and the Naval Medical Research Command Clinical Trials Center in Bethesda.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.